Premium
Drug Treatments in Development for Alzheimer's Disease
Author(s) -
Woodward Michael C
Publication year - 2012
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/j.2055-2335.2012.tb00133.x
Subject(s) - medicine , disease , dementia , drug development , inflammation , oxidative stress , drug , neurogenesis , bioinformatics , alzheimer's disease , intensive care medicine , neuroscience , psychiatry , pathology , biology
ABSTRACT New therapies are needed to combat the symptoms and underlying disease processes in the dementias. A rapid increase in our understanding of the risk factors for dementia and the underlying pathologies has not been matched with new effective therapies. In this review, potential new symptomatic and disease‐modifying therapies will be described. Most are directed at modifying the amyloid cascade that seems to be the primary pathogenic feature of Alzheimer's disease, other targets include tau pathology, inflammation, neurogenesis and oxidative stress. Some of these therapies may be beneficial for other dementias. It is sobering that in 2012 we only have 4 drugs that are modestly effective for the features of one dementia.